GSK Announces Job Cuts in Vaccine Manufacturing Restructuring
GlaxoSmithKline (NYSE: GSK) announced plans to close its Dresden, Germany vaccine manufacturing facility by summer 2027, impacting 641 jobs. The decision is driven by declining demand for traditional egg-based flu vaccines and a strategic shift toward newer mRNA technology. GSK will consolidate production at its Ste-Foy site in Canada, which it believes can meet future demand more sustainably and competitively. The move aims to improve cost efficiency by eliminating excess capacity from an aging segment of the influenza market. This restructuring is expected to strengthen margins as vaccine sales remain a key earnings driver for GSK, with second-quarter 2026 revenue rising 8% year-over-year. The company's mRNA-based flu vaccine has shown promising Phase II results and is now in Phase III trials. However, the closure highlights risks related to declining traditional vaccine demand before newer products can compensate. There are also potential costs from restructuring and possible opposition from German unions.
Tickers: $GSK
Topics: job cuts mRNA vaccines restructuring vaccine manufacturing